Last reviewed · How we verify
Erdos capsule
Erdos capsule works by inhibiting the reuptake of norepinephrine, a neurotransmitter that plays a key role in attention and arousal.
Erdos capsule works by inhibiting the reuptake of norepinephrine, a neurotransmitter that plays a key role in attention and arousal. Used for Attention deficit hyperactivity disorder (ADHD).
At a glance
| Generic name | Erdos capsule |
|---|---|
| Sponsor | Kwang-Ha Yoo |
| Drug class | norepinephrine reuptake inhibitor |
| Target | norepinephrine transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
By blocking the reuptake of norepinephrine, Erdos capsule increases the levels of this neurotransmitter in the brain, leading to increased alertness and attention. This mechanism is thought to be responsible for the drug's therapeutic effects in treating attention deficit hyperactivity disorder (ADHD).
Approved indications
- Attention deficit hyperactivity disorder (ADHD)
Common side effects
- Increased heart rate
- Insomnia
- Anxiety
Key clinical trials
- Evaluate the Efficacy and Safety of Acute Bronchitis Symptoms Improvement for Bronpass Tab. Compared to Erdos Capsule (PHASE4)
- Drug Interaction Study Between Erdosteine and Bepotastine Besilate in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Erdos capsule CI brief — competitive landscape report
- Erdos capsule updates RSS · CI watch RSS
- Kwang-Ha Yoo portfolio CI